Results accumulate gradually, particularly with consistent use
Loren Pickart's foundational 1973 characterization of GHK as a plasma growth-promoting peptide opened a research line that now extends across wound healing, skin remodeling, antioxidant gene expression, and anti-inflammatory regulation [9,10]
For elution of the target protein, the interaction to the ligand is resolved by changing the buffer conditions, for example, the pH value, or by adding a specific competitor that supplants the target protein from the ligand resulting in dissociation of the target, while the ligand remains immobilized on the stationary phase
Some users experience no adverse effects whatsoever while others encounter noticeable injection site reactions that require management strategies
The standard dose is 1000 mcg (1 mg) per month